Field Trip Health (CSE: FTRP) is growing up. The company this morning announced that it is set to uplist to the Toronto Stock Exchange as of next week, and will delist from the Canadian Securities Exchange as a result.
The company will see its equity move to the big board as of June 7, 2021, with the firm to continue trading under the symbol “FTRP”. Liekwise, its warrants are to be listed under the symbol “FTRP.wt”. The firms US listing will be unaffected by the move.
As a result of the move, the company has reworked its board of directors slightly, with the appointments of Barry Fishman and Ellen Lubman. Fishman most recently served as the CEO of Vivo Cannabis, prior to which he served as an independent director for Aurora Cannabis and Canopy Growth. Lubman meanwhile is currently chief business officer of Werewolf Therapeutics, prior to which she served in a similar role for Impel NeuroPharma among other roles.
Field Trip Health last traded at $5.03 on the CSE.
Information for this analysis was found via Sedar and Field Trip Health. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.